Skip to main content
. Author manuscript; available in PMC: 2018 Jan 22.
Published in final edited form as: Curr Opin Rheumatol. 2016 Jul;28(4):359–367. doi: 10.1097/BOR.0000000000000301

Figure 2. Targeting IL-17/IL-23 pathway with neutralizing agents.

Figure 2

IL-23 is a heterodimer of p40 (IL-12p40) and p19 (IL-23p19). Ustekinumab binds to IL-12p40 and blocks the binding of both IL-12 and IL-23 to their receptors. BI655066 binds sIL-23p19 and block the binding of IL-23 to IL-23R. Secukinumab and ixekizumab bind IL-17A and block the binding of both IL-17A and IL-17A/F to their receptor. Bimekizumab and MSB0010841 bind and neutralize both IL-17A and IL-17F isoforms. Brodalumab binds IL-17RA and blocks the binding of IL-17A, IL-17A/F, IL-17F, IL-17C, and IL-17E to their receptors. Fezakinumab binds and neutralizes IL-22.